Registration Dossier

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

FAT40825/A is expected to have a low bioaccumulation potential in the human body and also is poorly absorbed by oral and dermal route (10% absorption expected conservatively). Due to its fine particle size the substance is capable of reaching the alveolar region in the lungs and thus inhalative absorption might be higher (80% absorption rate proposed). However, it should be noted that FAT40825 is only placed onto the market in a dedusted form respectively in a granulated form and thus in practical handling and use inhalation of dust particles is technically minimized.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential
Absorption rate - oral (%):
Absorption rate - dermal (%):
Absorption rate - inhalation (%):

Additional information

Due to the physico-chemical properties (i.e., high molecular weight, high water solubility, particle size is less than 10 µm, low LogPow) FAT40825/A is expected to be absorbed in human body via different routes - oral (assumed 10%), dermal (assumed 10%) and inhalation (assumed 80%). Following absorption, FAT40825/A is anticipated to be distributed in blood, lung, liver and kidney. Excretion is expected via urine, bile or feces, and as a conclusion FAT 40825/A has a poor accumulation potential in the human body.